--- title: "ImmunityBio (IBRX) news: offering, lawsuit and settlement" url: "https://aibio.space/companies/immunitybio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IBRX offering, lawsuit and settlement news: ImmunityBio adds up to $459,972,480 to its at-the-market stock program. ImmunityBio, Inc." --- IBRX ImmunityBio, Inc. NASDAQ · United States # ImmunityBio (IBRX) news IBRX offering, lawsuit and settlement news Company Updates · 2026-05-15 ## [MiNK starts randomized Phase 2 trial in acute lung injury](https://aibio.space/news/mink-starts-randomized-phase-2-trial-acute-lung-injury/) MiNK reported first quarter 2026 results and said cash and cash equivalents were approximately $9.5 million at March 31, 2026. Preliminary data from the trial are expected in the second half of 2026. ## Latest ImmunityBio news 1. 2025-12-29 Financings [ImmunityBio adds up to $459,972,480 to its at-the-market stock program](https://aibio.space/news/immunitybio-adds-up-459-972-480-market-stock-program/) The company amended its sales agreement with Jefferies and filed a new prospectus supplement. It also confirmed a higher authorized share count. 2. 2025-08-08 Legal [ImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement](https://aibio.space/news/immunitybio-gets-preliminary-court-approval-shareholder-derivative/) A federal court preliminarily approved the settlement of three shareholder derivative suits naming ImmunityBio's current and former officers and directors. The company agrees to governance reforms and expects its insurer to pay the plaintiffs' attorneys' fees, which their counsel plans to ask the court to set at up to $1,400,000. The final hearing is November 4, 2025. ## ImmunityBio at a glance - **Ticker**: IBRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $357.4 million ### Related companies - [Minerva Neurosciences](https://aibio.space/companies/minerva-neurosciences/) NASDAQ: NERV - [Innovation Pharmaceuticals](https://aibio.space/companies/innovation-pharmaceuticals/) OTC: IPIX - [OnKure Therapeutics](https://aibio.space/companies/onkure-therapeutics/) NASDAQ: OKUR - [Northwest Biotherapeutics](https://aibio.space/companies/northwest-biotherapeutics/) OTC: NWBO - [Cocrystal Pharma](https://aibio.space/companies/cocrystal-pharma/) NASDAQ: COCP - [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) NASDAQ: BMEA - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) NASDAQ: TKNO ### Also on NASDAQ - [Incyte](https://aibio.space/companies/incyte/) INCY - [Bon Natural Life](https://aibio.space/companies/bon-natural-life/) BON - [Revolution Medicines](https://aibio.space/companies/revolution-medicines/) RVMD - [Clearmind Medicine](https://aibio.space/companies/clearmind-medicine/) CMND - [EXAGEN INC.](https://aibio.space/companies/exagen/) XGN - [Universe Pharmaceuticals](https://aibio.space/companies/universe-pharmaceuticals/) UPC ## ImmunityBio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$113.3 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | [$14.7 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | | Research and development | | [$190.1 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/) | | Net income (loss) | [-$351.4 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | [-$413.6 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | | Cash from operations | [-$304.9 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | [-$391.2 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | | Cash and equivalents | [$88.3 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/) | [$143.4 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | | Short-term investments | [$154.5 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/) | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $75.7 million, plus short-term investments of $281.7 million, $357.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ImmunityBio Has ImmunityBio raised money recently? Our latest story on this, dated Dec 29, 2025: "ImmunityBio adds up to $459,972,480 to its at-the-market stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunitybio-adds-up-459-972-480-market-stock-program/). Is ImmunityBio involved in a lawsuit? Our latest story on this, dated Aug 8, 2025: "ImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunitybio-gets-preliminary-court-approval-shareholder-derivative/). Has ImmunityBio settled a lawsuit? Our latest story on this, dated Aug 8, 2025: "ImmunityBio gets preliminary court approval of shareholder derivative lawsuit settlement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immunitybio-gets-preliminary-court-approval-shareholder-derivative/). What is the ticker symbol of ImmunityBio? ImmunityBio, Inc. trades under the ticker IBRX on NASDAQ. Where is ImmunityBio listed? ImmunityBio, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:26CA; FWB:26CA; GETTEX:26CA; HAM:26CA; HAN:26CA; LS:A2QQ2E; LSX:A2QQ2E; MUN:26CA; SWB:26CA; TRADEGATE:26CA; XETR:26CA. What is the SEC CIK of ImmunityBio? The SEC Central Index Key (CIK) for ImmunityBio, Inc. is 1326110. Its filings are on SEC EDGAR. How many shares does ImmunityBio have outstanding? 1,059,836,273 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is ImmunityBio listed under? Our directory records ImmunityBio, Inc. under United States. What does ImmunityBio do? Our directory classifies ImmunityBio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of ImmunityBio? The ISIN recorded for ImmunityBio, Inc. is US45256X1037. Does aibio.space cover ImmunityBio? aibio.space lists ImmunityBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ImmunityBio incorporated? SEC records list its state or country of incorporation as DE. What was ImmunityBio's revenue last year? $113.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is ImmunityBio profitable? ImmunityBio, Inc. reported a net loss of $351.4 million for the fiscal year ended Dec 31, 2025, and used $304.9 million of cash in operations, per its annual report to the SEC. How much cash does ImmunityBio have? $357.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: ImmunityBio Members talk about ImmunityBio (IBRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ImmunityBio, newest first. Each line links the filing it comes from. 1. 2025-12-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1326110/000119312525331242/d19212d424b5.htm) 2. 2025-08-08 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326110/000119312525177024/d29656dex991.htm) 3. 2025-07-25 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/d20571dex991.htm) 4. 2025-04-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326110/000119312525075102/d943675dex991.htm) 5. 2025-03-19 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000040/ibrx-20250313.htm) 6. 2025-03-03 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm) 7. 2024-12-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1326110/000119312524274413/d851020d424b5.htm) 8. 2024-11-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1326110/000132611024000111/ibrx-20240930.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IBRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-IBRX/). ## SEC filings and registration - **SEC name**: ImmunityBio, Inc. - **CIK**: 1326110 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: IBRX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121 - **Phone**: (844) 696-5235 - **Shares outstanding**: 1,059,836,273 as of 2026-07-31 (10-Q filed 2026-08-04) - **Former names**: NantKwest, Inc.; Conkwest, Inc.; ZelleRx Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1326110/000119312526421820/d188887d8k.htm) filed 2026-10-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/ibrx-20260729.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000064/ibrx-20260609.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1326110/000119312526229153/d75270d8k.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000059/ibrx-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000057/ibrx-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001326110), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ImmunityBio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IBRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ImmunityBio, Inc. - **Ticker**: IBRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US45256X1037 - **Other listed symbols**: DUS:26CA; FWB:26CA; GETTEX:26CA; HAM:26CA; HAN:26CA; LS:A2QQ2E; LSX:A2QQ2E; MUN:26CA; SWB:26CA; TRADEGATE:26CA; XETR:26CA - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IBRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/immunitybio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ImmunityBio (IBRX) news: offering, lawsuit and settlement", 2026-10-31, https://aibio.space/companies/immunitybio/